Annotation Detail
Information
- Associated Genes
- BRD4
- Associated Variants
- BRD4 BRD4-NUTM1
- Associated Disease
- NUT midline carcinoma
- Source Database
- CIViC Evidence
- Description
- Treatment of the patient-derived 797 NMC cell line for 48 hours with JQ1 (500 nM) provoked terminal differentiation which was accompanied by growth arrest and sustained inhibition of proliferation. Non-BRD4-dependent cell lines including a squamous carcinoma cell line (TE10) failed to exhibit differentiation effects when treated with JQ1.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1781
- Gene URL
- https://civic.genome.wustl.edu/links/genes/9588
- Variant URL
- https://civic.genome.wustl.edu/links/variants/719
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- NUT Midline Carcinoma
- Evidence Direction
- Supports
- Drug
- JQ1
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 20871596
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| JQ1 | Sensitivity | true |